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Abstract
Background: The interpretation of trial results can be helped by understanding how generalisable they are to the
target population for which inferences are intended. INTERVAL, a large pragmatic randomised trial of blood donors
in England, is assessing the effectiveness and safety of reducing inter-donation intervals. The trial recruited mainly
from the blood service’s static centres, which collect only about 10 % of whole-blood donations. Hence, the extent
to which the trial’s participants are representative of the general blood donor population is uncertain. We compare
these groups in detail.
Methods: We present the CONSORT flowchart from participant invitation to randomisation in INTERVAL. We
compare the characteristics of those eligible and consenting to participate in INTERVAL with the general donor
population, using the national blood supply ’PULSE’ database for the period of recruitment. We compare the
characteristics of specific groups of trial participants recruited from different sources, as well as those who were
randomised versus those not randomised.
Results: From a total of 540,459 invitations, 48,725 donors were eligible and consented to participate in INTERVAL.
The proportion of such donors varied from 1–22 % depending on the source of recruitment. The characteristics of
those consenting were similar to those of the general population of 1.3 million donors in terms of ethnicity, blood
group distribution and recent deferral rates from blood donation due to low haemoglobin. However, INTERVAL
participants included more men (50 % versus 44 %), were slightly older (mean age 43.1 versus 42.3 years), included
fewer new donors (3 % versus 22 %) and had given more donations over the previous 2 years (mean 3.3 versus 2.2)
than the general donor population. Of the consenting participants, 45,263 (93 %) donors were randomised. Compared
to those not randomised, the randomised donors showed qualitatively similar differences to those described above.
Conclusions: There was broad similarity of participants in INTERVAL with the general blood donor population of
England, notwithstanding some differences in age, sex and donation history. Any heterogeneity of the trial’s results
according to these characteristics will need to be studied to ensure its generalisability to the general donor population.
Trial registration: Current Controlled Trials ISRCTN24760606. Registered on 25 January 2012.
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Background
One of the key roles of the National Health Service Blood
and Transplant (NHSBT) is to provide an efficient supply
of blood and blood components to hospitals in England
and North Wales. The INTERVAL trial is a parallel group,
pragmatic, individually randomised controlled trial (RCT)
which aimed to recruit approximately 50,000 blood do-
nors registered with NHSBT [1]. INTERVAL seeks to ad-
dress an important question for NHSBT and potentially
blood services worldwide: What is the optimum frequency
of whole-blood donation to enhance blood supplies and
maintain donors’ health? The trial is sufficiently powered
to provide evidence on whether donation intervals should
be tailored to donor subgroups who are more or less sus-
ceptible to iron deficiency [2]. The trial’s objectives are
driven by the need to meet the dual potential challenge of
increases in demand for blood as the population ages, and
difficulties in attracting new blood donors [3–5].
Giving a unit (about 0.5 litres) of whole blood is the
most common type of blood donation and differs from
other donations involving the collection of specific blood
components such as red cells, platelets or plasma. In
current NHSBT practice, male and female whole-blood
donors can give blood as frequently as every 12 and
16 weeks, respectively. During their 2-year involvement
in the INTERVAL trial, participants were randomised to
give blood at either these standard donation intervals or
more often, specifically every 12, 10 or 8 weeks for men
and 16, 14 or 12 weeks for women. The trial’s primary
outcome is the number of whole-blood units donated
over 2 years, and the key secondary outcome is the Short
Form Survey-36 composite measure of physical well-
being at 2 years [6]; the trial’s statistical analysis plan is
provided in Additional file 1. A criticism of research
studies (especially RCTs) is a lack of consideration for
external validity and whether the findings are generalis-
able to a wider setting than that in which they were
initially tested [7]. Therefore, the extent to which the
trial’s main findings (due to be reported in 2017) are ap-
plicable to future donation strategies will be influenced
by how representative the INTERVAL participants are of
the general donor population.
Anyone between the ages of 17 and 65 years can regis-
ter with NHSBT as a blood donor; once registered a
donor may continue donating up to and beyond 65 years
old if they meet all usual criteria for giving blood. In
2013, more than 1.7 million whole-blood donations were
made by almost 1 million donors at more than 23,000
donation venues across England and North Wales [8].
Approximately 90 % of these donations were made at
community venues or ‘mobile sessions’ (e.g. village halls,
local schools). The remaining 10 % were made at the 25
premises run by NHSBT as ‘static’ donor centres across
England. The relatively small proportion of whole-blood
collections at the static donor centres reflects the
focus, at that time, on the collection of platelet dona-
tions at these sites.
In this paper we describe recruitment to INTERVAL
and investigate how representative the trial participants
were of the general donor population.
Methods
Selection and recruitment of participants
Recruitment of donors to the INTERVAL trial took
place between June 2012 and June 2014. Donors were
eligible to join the trial if they were aged 18 years or
older (to meet ethical requirements, with the normal
lower age limit for donation being 17 years old), fulfilled
all routine criteria for blood donation, were willing to be
randomised to any of the trial’s intervention groups and
had an email address and access to the Internet (since
the trial collects data mainly via remote and web-based
methods). In addition, donors had to be willing to give
blood at one of the 25 static donor centres; this condi-
tion was necessary to overcome NHSBT information
technology safeguards to prevent donors giving at less
than standard donation intervals.
Invitations were sent to specific groups (or ‘sources’)
of donors during the recruitment period (Table 1). Ini-
tially postal invitations were sent to donors registered at
one of the 25 static donor centres. However, in order to
meet the trial’s recruitment target, we broadened the
pool of potential participants by extending postal or
email invitations to mobile session donors thought to be
most likely to join the trial (and transfer to a static
donor centre); email was preferred for large groups in
order to reduce costs. In particular, we approached mo-
bile session donors either because they had previously
agreed to give platelet donations at static centres or be-
cause of the donor’s proximity to a static donor centre
(judged by the location of their usual mobile session or
NHSBT correspondence address). In addition, donors
arriving at a static donor centre who had not received an
invitation could also be informed about INTERVAL.
Donors expressing an interest in the trial, and able to
donate following NHSBT’s routine screening, were asked
to complete the trial consent form prior to giving their
usual donation [1]. Donors who were temporarily unable
to donate (for reasons such as failure to meet haemoglo-
bin thresholds, recent overseas travel) had the opportun-
ity to join the trial at their next donation visit, as long as
the visit occurred within the recruitment period.
Data collection
Data used to populate the CONSORT flowchart were
derived from NHSBT’s national blood supply database
(PULSE) and the INTERVAL trial’s research database.
PULSE covers all aspects of donor and donation
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management: procedure codes are added to donors’ re-
cords according to the type of donations given (e.g.
platelet, whole-blood), and communication codes are
used to record types of messages sent to donors. New
communication codes were added to PULSE for donors
invited to join INTERVAL from different sources
(Table 1), along with procedure codes to enable tracking
of INTERVAL participants [1]. Further communication
codes were placed on the records of donors who, on at-
tending a static donor centre during the recruitment
period, expressed an interest in and/or enrolled in the
study.
These enrolment codes served to activate the secure
transfer of participants’ trial-relevant data from PULSE to
the INTERVAL research database (held at the academic co-
ordinating centre at the University of Cambridge). Receipt
of these data then triggered an email from the academic
coordinating centre requesting consenting participants to
complete the INTERVAL baseline questionnaire. Only
those consenting participants who responded to this initial
online questionnaire were subsequently randomised into
the trial [1].
The PULSE database was also used to create a bespoke
dataset on all registered NHSBT blood donors to com-
pare the characteristics of the INTERVAL cohort with
the general donor population. This dataset consisted of
entries for 3,362,757 donors, including INTERVAL par-
ticipants (identified by an anonymous study number).
Information retrieved included individual-level data on
donors’ sex, age and ethnicity, ABO and Rhesus D blood
group, NHSBT registration date, date of first attendance
for donation (whether successful or not), date of first
successful donation and detailed information on the out-
comes of each attendance over the past 7 years. Geographic
reference data, held on PULSE, were used to calculate
distances between donors’ correspondence address and
their nearest static donor centre.
Data analysis
The INTERVAL cohort is defined as blood donors who
completed a consent form and were eligible to join the
study. The INTERVAL trial comprises participants who
additionally completed the baseline questionnaire and
were randomised.
In defining recruitment source, participants receiving
an invitation following their enrolment were deemed
not to have received a postal/email invitation. Where
participants had received more than one postal/email
invitation type during the recruitment period, the invi-
tation immediately prior to their enrolment in the study
was used to indicate their source of recruitment. For
donors who did not join the study and were sent more
than one invitation, the first one sent was taken as their
invitation type.
The general donor population, used as a comparator,
was defined as all donors registered with NHSBT who
did not consent to INTERVAL but had attended an ap-
pointment during the INTERVAL recruitment period
(11 June 2012 – 14 June 2014); see Fig. 1. To define
donor characteristics it was necessary to fix an appropri-
ate reference date. For INTERVAL participants this date
corresponded to the date of their baseline attendance.
For the general donor population, it was defined as par-
ticipants’ date of attendance nearest to the mid-point
of the INTERVAL recruitment period (12 June 2013).
Age at baseline was calculated from the attendance
date and recorded date of birth. Ethnicity and ABO/
Rhesus D blood group were as recorded on NHSBT’s
PULSE database.
The focus of the analysis is on the magnitude of differ-
ences between groups rather than their statistical signifi-
cance. Given the very large numbers, even very small
differences can have extreme P values. Hence, differ-
ences with 95 % confidence intervals (CI) are presented
rather than P values.
Results
Participant recruitment
Figure 2 summarises the status of participants at dif-
ferent stages of recruitment. Between June 2012 and
October 2013, more than 500,000 blood donors were
sent an invitation, just under 100,000 attended one of
the 25 static donor centres during the recruitment
period and of these 44 % expressed an interest in joining
Table 1 Description of recruitment sources for the INTERVAL trial
Recruitment source Source description Invitation period Invitation type
Centre Donors registered at a static donor centre Jun 2012 – Jan 2013 Letter
Mobile (platelet) Mobile session donors who had previously registered an interest in giving
platelets at a static donor centre
Jan 2013 – Oct 2013 Letter
Mobile (10-mile) Donors giving blood at a mobile session within 10 miles of a static donor centre Jan 2013 – Oct 2013 Letter or email
Mobile (30-mile) Donors with a correspondence address within 30 miles (but typically 20 miles)
of a static donor centre
Jan 2013 – Oct 2013 Email
No invitation Donors giving blood at a static donor centre who expressed an interest in joining
the trial but who did not receive a previous invitation
Jun 2012 – Jun 2014 Not applicable
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the trial and (on initial questioning) met the age and Inter-
net/email criteria. There was a further group of approxi-
mately 11,000 donors who did not receive an invitation
but who attended a recruitment centre for donation
and responded positively when asked by donor-centre
staff if they wished to enrol (the denominator for this
group is unknown).
Data collected by donation staff using a pre-defined
questionnaire indicated that the main reason given for
not wanting to join the study was the time commitment
required (41 % of donors who gave a reason). About
16 % of donors wanted greater flexibility with respect to
donation appointments, 6 % were concerned about the
donation frequency, 7 % were being evaluated as poten-
tial platelet donors, 1 % disagreed with the aims of the
study and 29 % indicated that they had other reasons for
not joining.
The majority of donors who expressed an initial inter-
est in the trial then gave their consent to join the
INTERVAL cohort (93 %) with only a small proportion
who either did not meet the study/donation criteria or
for other reasons decided not to enrol. Only those mem-
bers of the INTERVAL cohort who completed the trial’s
baseline questionnaire were subsequently randomised; as
such the INTERVAL trial represents 93 % of the INTER-
VAL cohort (and 87 % of all those expressing an inter-
est). The numbers of male and female randomised
donors were similar, and there was an even split of do-
nors into the gender-specific treatment allocations.
Participation by sources of recruitment
The participation by subgroups of donors according to
their sources of recruitment is shown in Table 2. The
largest group of INTERVAL participants (31,945) came
from the pool of donors who had attended a static donor
centre prior to recruitment — this group showed the
highest consent rate to the INTERVAL cohort (22.1 % of
all invitations sent) and trial recruitment (20.4 %). In
contrast, the recruitment rate was lower in mobile ses-
sion donors who either donated within 10 miles (2.8 %)
or had a correspondence address within 30 miles (1.3 %)
of a static donor centre. As these sources were of a
considerable size, however, their contribution to the
INTERVAL cohort was not insubstantial (7,649 partici-
pants). The recruitment rate from the Mobile (platelet)
group was higher than from the other mobile session re-
cruitment sources, as expected due to their prior willing-
ness to transfer to a static donor centre. However, as
this group represented a small pool of donors, the over-
all number of recruited participants from this source
was relatively small.
Comparison of INTERVAL donors to the general donor
population
The INTERVAL cohort represented approximately 4 %
of NHSBT’s 1.3 million general donor population. The
characteristics of these groups are compared in Tables 3
and 4. Some notable differences were that the INTER-
VAL cohort included more men (50 % versus 44 %),
were slightly older (mean age: 43.1 versus 42.3 years,
with a lower proportion of 17–24 year olds: 13 % versus
18 %) and lived closer to a static donor centre (62 % ver-
sus 19 % within 0–4 miles, partly by design). In both
samples the majority of individuals (91 %) reported their
ethnicity as ‘white’ (Table 3); however, after excluding
donors with missing values (Table 4), this proportion
was slightly lower in the INTERVAL cohort. The distri-
bution of blood groups was similar. By design the entire
INTERVAL cohort attended a static donor centre at
baseline. Several factors suggest that the INTERVAL co-
hort was a more long-standing and dedicated group of
donors: they had a slightly longer history of donation
with NHSBT (10.7 versus 8.6 years), a much lower pro-
portion of new donors (3 % versus 22 %) and had given,
on average, more whole-blood donations during the
2 years prior to baseline (mean 3.2 versus 2.1). The pro-
portion of donors with a deferral over the previous 2 years
(both for low haemoglobin and any other reason) ap-
peared higher in the INTERVAL cohort. However, when
this is expressed relative to the average number of whole-
blood donations given, the deferral rate for low haemoglo-
bin is similar to that in the general donor population (i.e.
2.1 % and 2.3 % per donation, respectively).
Fig. 1 Flow diagram showing the selection of donors forming the NHSBT general donor population
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Geographical distribution of donors
Figure 3 compares the geographical distribution of
the INTERVAL cohort and NHSBT’s general donor
population. For the most part, the proportion of
INTERVAL participants in each of the ten regions
was fairly similar to the general donor population. Re-
gions in which the density of static donor centres is
high (i.e. London, Yorkshire and the Humber and
North West) showed the highest proportions of
INTERVAL donors, which most notably exceeded
those for the general donor population. The opposite
was true in the South East and the North East, where
there are very few static donor centres in relation to
the size and density of the donor population, and in
Wales, where there are none.
Comparison of randomised versus non-randomised donors
Tables 3 and 4 also compare characteristics of partici-
pants finally randomised in the INTERVAL trial against
those not randomised, primarily due to non-completion
Invitation sent 540459
Attended Donation 95185
Attended Donor Centre during
recruitment period
Excluded 445274
Did not attend donation at Donor Centre
during recruitment period
Excluded 53499
Not interested or ineligible as < 18y old
and/or no access to internet/ email1
Expressed interest 41686
Expressed interest 108342
Consented and eligible
INTERVAL cohort 48725
Excluded 3795
Eligible, did not consent (1265)
Ineligible, donation criteria not met
(2489) for reasons including low Hb -
1007, medical - 535, infection/contact -
203, administrative - 296, failed
venepuncture -118, travel - 94, Clinical
- 75, skin piercing - 61, surgery - 52,
other - 15, false reaction - 12,
vaccination - 9, apheresis sample - 6,
blood pressure -5, malaria test - 1.
Ineligible, aged <18 years (41)
INTERVAL trial 45263
Excluded 3462
No email address (125)
Participant withdrawal (134)
Non-completion of questionnaire (3176)
Other reasons (27)
Men 22466
randomised
Women 22797
randomised
8-wk 7485 10-wk 7490 12-wk 7491 14-wk 759912-wk 7600 16-wk 7598
Fig. 2 CONSORT flowchart of participants into the INTERVAL trial. 1On arrival at the donor centre, donation staff in the welcome area asked
donors if they were interested in joining, were ≥18 years old and had access to email/Internet. If a donor responded ‘no’ to any of these
questions, he/she was excluded. 2This group expressed an interest in joining the study when asked by donation staff in the welcome area,
but had not previously received an invitation
Table 2 Breakdown of CONSORT flowchart according to source of recruitment
Invitations Exclusions: Post-attendance
and prior to consent
INTERVAL cohort and trial
Recruitment source Invited Attended donation INTERVAL cohort Randomised Not randomised
Centre 144,852 71,445 (49.3 %) 39,500 31,945 (22.1 %) 29,549 2396
Mobile (platelet) 21,585 2330 (10.8 %) 586 1744 (8.1 %) 1696 48
Mobile (10-mile) 190,081 15,886 (8.4 %) 10,648 5238 (2.8 %) 5009 229
Mobile (30-mile) 183,941 5524 (3.0 %) 3113 2411 (1.3 %) 2325 86
No invitationa - 10,834 - 3447 7387 - 6684 703
Total 540,459 106,019 57,294 48,725 45,263 3462
aWalk-in donors without a previous invitation; no denominator available
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Table 3 Demographic characteristics of the NHSBT general donor population and of the INTERVAL cohort and trial
Demographics INTERVAL cohort
n (%) or mean (SD) INTERVAL cohort NHSBT general donor
population
Randomised in INTERVAL
trial
Not randomised
All donors 48,692 (100.0 %)a 1,330,506 (100.0 %) 45,235 (100.0 %)a 3457 (100.0 %)
Sex
Male 24,212 (49.7 %) 586,372 (44.1 %) 22,456 (49.6 %) 1756 (50.8 %)
Female 24,480 (50.3 %) 744,134 (55.9 %) 22,779 (50.4 %) 1701 (49.2 %)
Age at baseline (years) 43.1 (14.3) 42.3 (15.0) 43.3 (14.2) 39.9 (14.7)
Age at baseline
17–24 6424 (13.2 %) 234,367 (17.6 %) 5679 (12.6 %) 745 (21.6 %)
25–34 10,236 (21.0 %) 235,238 (17.7 %) 9468 (20.9 %) 768 (22.2 %)
35–44 9095 (18.7 %) 246,225 (18.5 %) 8500 (18.8 %) 595 (17.2 %)
45–-54 11,158 (22.9 %) 304,927 (22.9 %) 10,456 (23.1 %) 702 (20.3 %)
55–-64 8822 (18.1 %) 221,143 (16.6 %) 8362 (18.5 %) 460 (13.3 %)
65+ 2957 (6.1 %) 88,606 (6.7 %) 2770 (6.1 %) 187 (5.4 %)
Ethnicity
White 44,192 (90.8 %) 1,207,593 (90.8 %) 41,259 (91.2 %) 2933 (84.8 %)
Asian 1127 (2.3 %) 31,829 (2.4 %) 941 (2.1 %) 186 (5.4 %)
Black African 118 (0.2 %) 3852 (0.3 %) 105 (0.2 %) 13 (0.4 %)
Black Caribbean 307 (0.6 %) 4971 (0.4 %) 271 (0.6 %) 36 (1.0 %)
Black other 31 (0.1 %) 743 (0.1 %) 29 (0.1 %) 2 (0.1 %)
Chinese 164 (0.3 %) 3831 (0.3 %) 141 (0.3 %) 23 (0.7 %)
Mixed 679 (1.4 %) 14,838 (1.1 %) 606 (1.3 %) 73 (2.1 %)
Other 138 (0.3 %) 3558 (0.3 %) 122 (0.3 %) 16 (0.5 %)
Unknown 1936 (4.0 %) 59,291 (4.5 %) 1761 (3.9 %) 175 (5.1 %)
Blood group
A RhD positive (A+) 14,737 (30.3 %) 397,277 (29.9 %) 13,768 (30.4 %) 969 (28.0 %)
A RhD negative (A-) 3744 (7.7 %) 97,450 (7.3 %) 3489 (7.7 %) 255 (7.4 %)
B RhD positive (B+) 4244 (8.7 %) 102,650 (7.7 %) 3877 (8.6 %) 367 (10.6 %)
B RhD negative (B-) 1070 (2.2 %) 27,317 (2.1 %) 993 (2.2 %) 77 (2.2 %)
O RhD positive (O+) 17,642 (36.2 %) 460,501 (34.6 %) 16,398 (36.3 %) 1244 (36.0 %)
O RhD negative (O-) 5542 (11.4 %) 138,349 (10.4 %) 5138 (11.4 %) 404 (11.7 %)
AB RhD positive (AB+) 1293 (2.7 %) 33,817 (2.5 %) 1199 (2.7 %) 94 (2.7 %)
AB RhD negative (AB-) 402 (0.8 %) 9550 (0.7 %) 368 (0.8 %) 34 (1.0 %)
Unknown 18 (0.0 %) 63,595 (4.8 %) 5 (0.0 %) 13 (0.4 %)
Distance to nearest static donor centre (miles)b
0–4 30,405 (62.4 %) 252,068 (18.9 %) 27,971 (61.8 %) 2434 (70.4 %)
5–9 9801 (20.1 %) 245,652 (18.5 %) 9236 (20.4 %) 565 (16.3 %)
10–29 7203 (14.8 %) 584,850 (44.0 %) 6832 (15.1 %) 371 (10.7 %)
30–59 775 (1.6 %) 220,388 (16.6 %) 730 (1.6 %) 45 (1.3 %)
60+ 98 (0.2 %) 18,045 (1.4 %) 93 (0.2 %) 5 (0.1 %)
Unknown 410 (0.8 %) 9503 (0.7 %) 373 (0.8 %) 37 (1.1 %)
Donor status at baselinec
New 1392 (2.9 %) 288,653 (21.7 %) 1147 (2.5 %) 245 (7.1 %)
Occasional 7912 (16.2 %) 226,507 (17.0 %) 7053 (15.6 %) 859 (24.8 %)
More frequent 39,388 (80.9 %) 815,346 (61.3 %) 37,035 (81.9 %) 2353 (68.1 %)
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Table 3 Demographic characteristics of the NHSBT general donor population and of the INTERVAL cohort and trial (Continued)
Demographics INTERVAL cohort
n (%) or mean (SD) INTERVAL cohort NHSBT general donor
population
Randomised in INTERVAL
trial
Not randomised
Donations (over last 2 years prior to baseline)d
All donations 3.28 (2.00) 2.24 (2.37) 3.33 (2.00) 2.61 (1.92)
Whole-blood donations 3.19 (1.81) 2.08 (1.87) 3.23 (1.80) 2.55 (1.80)
Other donations 0.10 (1.05) 0.16 (1.64) 0.10 (1.07) 0.06 (0.79)
Deferrals (during the 2 years prior to baseline)e
Deferral for low haemoglobin 3308 (6.8 %) 63,071 (4.7 %) 3094 (6.8 %) 214 (6.2 %)
Any other deferral 14,628 (30.0 %) 327,747 (24.6 %) 13,632 (30.1 %) 996 (28.8 %)
Length of NHSBT donation history at baseline (years)f 10.7 (8.4) 8.58 (8.44) 10.9 (8.4) 8.47 (8.02)
Venue type attended at baselineg
Static centre 48,692 (100.0 %) 99,724 (7.5 %) 45,235 (100.0 %) 3457 (100.0 %)
Mobile 0 (0.0 %) 1,230,782 (92.5 %) 0 (0.0 %) 0 (0.0 %)
aThe characteristics of 33 donors in the INTERVAL cohort (of whom 28 are in the INTERVAL trial) could not be identified in the PULSE database due to merged
donor records
bThe correspondence address (used to calculate ’Distance to nearest static donor centre’ and derive ’Region’) was correct at the time the data were extracted
from PULSE (Nov 2015). Historical correspondence addresses were not available in PULSE
c ’New’ has been defined according to the classification used by NHSBT, i.e. an individual who has not previously provided a full donation is considered to be a
new donor. ’Occasional’ and ’More frequent’ have been defined as less than or equal to two full donations in the last 5 years and more than two full donations in
the last 5 years, respectively
dIncluding donations where volume equals ’Normal’, ’Overweight’ or ’Missing’ (not including donations where volume equals ’Empty’ or ’Underweight’)
eDeferrals during the 2 years prior to baseline were summarised as counts of people with a deferral for low haemoglobin levels and more generally deferral for
reasons other than low haemoglobin
fLength of donation history with NHSBT at baseline was defined as the period of time between baseline and the minimum of date of registration, date of first
attendance (whether successful or not) and date of first successful donation
gFor venue type, some old venues that are no longer used do not have an associated PULSE venue code. In these cases, although venue type was missing,
because the only venues that were no longer being used were mobile venues, we have assumed that the venue type was mobile
SD, Standard deviation
Table 4 Differences (95 % CIs): INTERVAL cohort versus NHSBT general donor population and INTERVAL randomised versus not
randomised
Demographics INTERVAL cohort
mean or proportion (%)a INTERVAL
cohort
NHSBT general donor
population
Difference (95 % CI) Randomised Not randomised Difference (95 % CI)
Sex: Male (%) 49.7 % 44.1 % 5.7 % (5.2 %, 6.1 %) 49.6 % 50.8 % -1.2 % (-2.9 %, 0.6 %)
Age at baseline (years) 43.1 42.3 0.73 (0.59, 0.87) 43.3 39.9 3.37 (2.88, 3.86)
Ethnicity: White (%) 94.5 % 95.0 % -0.5 % (-0.7 %, -0.3 %) 94.9 % 89.4 % 5.5 % (4.5 %, 6.6 %)
Blood group: O (%)b 47.6 % 47.3 % 0.4 % (-0.1 %, 0.8 %) 47.6 % 47.9 % -0.2 % (-2.0 %, 1.5 %)
Distance to nearest static donor
centre (miles)
6.29 18.1 -11.8 (-12.0, -11.7) 6.37 5.24 1.12 (0.82, 1.43)
Number of all donationsc 3.28 2.24 1.04 (1.02, 1.06) 3.33 2.61 0.73 (0.66, 0.80)
Deferral for low haemoglobin (%)c 6.8 % 4.7 % 2.1 % (1.8 %, 2.3 %) 6.8 % 6.2 % 0.6 % (-0.2 %, 1.5 %)
Any other deferral (%)c 30.0 % 24.6 % 5.4 % (5.0 %, 5.8 %) 30.1 % 28.8 % 1.3 % (-0.2 %, 2.9 %)
Length of NHSBT donation history
at baseline (years)
10.7 8.58 2.15 (2.07, 2.22) 10.9 8.47 2.43 (2.14, 2.72)
aThose with missing values excluded
bBlood group O includes both RhD groups
cDuring the 2 years prior to baseline
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of the baseline questionnaire. Whereas the sex ratio was
comparable, randomised participants were slightly older
(mean age: 43 versus 40 years, with a lower proportion
aged 17–24 years: 13 % versus 22 %), were more likely
to be of white ethnicity (91 % versus 85 %), were more
likely to have been a frequent donor (82 % versus 68 %)
and had given a greater average number of donations in
the 2 years prior to baseline (3.3 versus 2.6). The groups
were similar in terms of the distribution of blood groups
and proportion of deferrals for both low haemoglobin
and any other reason. Surprisingly, the data do not sug-
gest that members of the INTERVAL cohort who had a
correspondence address at a greater distance from a
static donor centre were less likely to be randomised.
Comparison of donors by recruitment source
As shown in Table 5, the characteristics of the INTERVAL
cohort participants from the Centre, Mobile (10-mile) and
Mobile (30-mile) sources were generally similar (with
some differences as expected in the distances between do-
nors’ correspondence address and a static donor centre).
Both the Mobile (platelet) and ‘No invitation’ participants
showed characteristics distinct from other groups. The
Mobile (platelet) group showed a markedly greater pro-
portion of men and, from their donation history, were
shown to be an especially committed group of donors.
This group also had a lower proportion of participants
who were less than 35 years old and of blood group O
Rh(D) positive. In contrast, the ‘No invitation’ donors
showed the highest proportion of participants in the 17–
24 year age group, the highest proportion of new donors,
the shortest average history of donation and the fewest
donations in the 2 years prior to baseline.
Discussion
More than 45,000 blood donors have been successfully re-
cruited into the NHSBT-embedded INTERVAL trial, mak-
ing it the largest randomised study, worldwide, of the
impact of more frequent donations on blood supplies and
donor health. Unusually, our study had the ability to com-
pare directly a range of participants’ characteristics be-
tween the INTERVAL trial and the target population. We
found that there was broad similarity of participants in
INTERVAL with the general blood donor population of
England, notwithstanding some differences in age, sex
and donation history. These observations lend support to
the generalisability of the trial’s future results, at least for
NHSBT. Nevertheless, any heterogeneity of the trial’s re-
sults according to the characteristics listed above will
need to be studied to ensure its generalisability to the
general donor population (Additional file 1). The current
analysis also shows that a broad range of donors have par-
ticipated in INTERVAL, enabling future assessment of
Fig. 3 Geographical distribution of the INTERVAL cohort (NHSBT general donor population in brackets) by region
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Table 5 Demographic characteristics of the INTERVAL cohort by recruitment sourcea
Demographics INTERVAL cohort
n (%) or mean (SD) Centre Mobile (platelet) Mobile (10-mile) Mobile (30-mile) No invitation
All donors 31,929 (100.0 %) 1741 (100.0 %) 5237 (100.0 %) 2409 (100.0 %) 7376 (100.0 %)
Sex
Male 15,996 (50.1 %) 1379 (79.2 %) 2196 (41.9 %) 1110 (46.1 %) 3531 (47.9 %)
Female 15,933 (49.9 %) 362 (20.8 %) 3041 (58.1 %) 1299 (53.9 %) 3845 (52.1 %)
Age at baseline (years) 43.7 (14.4) 51.2 (13.2) 41.9 (11.7) 45.2 (13.6) 38.3 (14.2)
Age at baseline
17–24 3866 (12.1 %) 82 (4.7 %) 544 (10.4 %) 268 (11.1 %) 1664 (22.6 %)
25–34 6688 (20.9 %) 166 (9.5 %) 1102 (21.0 %) 365 (15.2 %) 1915 (26.0 %)
35–44 5849 (18.3 %) 263 (15.1 %) 1205 (23.0 %) 430 (17.8 %) 1348 (18.3 %)
45–54 7233 (22.7 %) 446 (25.6 %) 1576 (30.1 %) 612 (25.4 %) 1291 (17.5 %)
55–64 5938 (18.6 %) 495 (28.4 %) 797 (15.2 %) 734 (30.5 %) 858 (11.6 %)
65+ 2355 (7.4 %) 289 (16.6 %) 13 (0.2 %) 0 (0.0 %) 300 (4.1 %)
Ethnicity
White 28,924 (90.6 %) 1644 (94.4 %) 4774 (91.2 %) 2227 (92.4 %) 6623 (89.8 %)
Asian 790 (2.5 %) 12 (0.7 %) 83 (1.6 %) 36 (1.5 %) 206 (2.8 %)
Black African 78 (0.2 %) 1 (0.1 %) 13 (0.2 %) 2 (0.1 %) 24 (0.3 %)
Black Caribbean 201 (0.6 %) 5 (0.3 %) 38 (0.7 %) 21 (0.9 %) 42 (0.6 %)
Black other 24 (0.1 %) 0 (0.0 %) 2 (0.0 %) 3 (0.1 %) 2 (0.0 %)
Chinese 120 (0.4 %) 1 (0.1 %) 12 (0.2 %) 4 (0.2 %) 27 (0.4 %)
Mixed 451 (1.4 %) 11 (0.6 %) 67 (1.3 %) 33 (1.4 %) 117 (1.6 %)
Other 94 (0.3 %) 2 (0.1 %) 14 (0.3 %) 4 (0.2 %) 24 (0.3 %)
Unknown 1247 (3.9 %) 65 (3.7 %) 234 (4.5 %) 79 (3.3 %) 311 (4.2 %)
Blood group
A RhD positive (A+) 9414 (29.5 %) 635 (36.5 %) 1612 (30.8 %) 854 (35.5 %) 2222 (30.1 %)
A RhD negative (A-) 2405 (7.5 %) 209 (12.0 %) 371 (7.1 %) 207 (8.6 %) 552 (7.5 %)
B RhD positive (B+) 2783 (8.7 %) 121 (7.0 %) 436 (8.3 %) 258 (10.7 %) 646 (8.8 %)
B RhD negative (B-) 737 (2.3 %) 45 (2.6 %) 96 (1.8 %) 0 (0.0 %) 192 (2.6 %)
O RhD positive (O+) 11,589 (36.3 %) 485 (27.9 %) 1995 (38.1 %) 1073 (44.5 %) 2500 (33.9 %)
O RhD negative (O-) 3859 (12.1 %) 199 (11.4 %) 515 (9.8 %) 0 (0.0 %) 969 (13.1 %)
AB RhD positive (AB+) 880 (2.8 %) 40 (2.3 %) 164 (3.1 %) 0 (0.0 %) 209 (2.8 %)
AB RhD negative (AB-) 256 (0.8 %) 7 (0.4 %) 48 (0.9 %) 17 (0.7 %) 74 (1.0 %)
Unknown 6 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 12 (0.2 %)
Distance to nearest static donor centre (miles)
0–4 21,298 (66.7 %) 570 (32.7 %) 3446 (65.8 %) 508 (21.1 %) 4583 (62.1 %)
5–9 5778 (18.1 %) 471 (27.1 %) 1329 (25.4 %) 818 (34.0 %) 1405 (19.0 %)
10–29 3946 (12.4 %) 649 (37.3 %) 377 (7.2 %) 1057 (43.9 %) 1174 (15.9 %)
30–59 538 (1.7 %) 36 (2.1 %) 37 (0.7 %) 13 (0.5 %) 151 (2.0 %)
60+ 68 (0.2 %) 2 (0.1 %) 7 (0.1 %) 7 (0.3 %) 14 (0.2 %)
Unknown 301 (0.9 %) 13 (0.7 %) 41 (0.8 %) 6 (0.2 %) 49 (0.7 %)
Donor status at baseline
New 453 (1.4 %) 0 (0.0 %) 6 (0.1 %) 8 (0.3 %) 925 (12.5 %)
Occasional 4180 (13.1 %) 35 (2.0 %) 1039 (19.8 %) 411 (17.1 %) 2247 (30.5 %)
More frequent 27,296 (85.5 %) 1706 (98.0 %) 4192 (80.0 %) 1990 (82.6 %) 4204 (57.0 %)
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the impact of increased donation frequency in relevant
subgroups.
INTERVAL required a substantial commitment from
donors: blood donations at regular (and more frequent
than usual) intervals over a 2-year period and comple-
tion of online questionnaires every 6 months. Exclusion
criteria were kept to a minimum, and all eligibility cri-
teria were necessary for operational considerations (at-
tendance at a static donor centre), ethics requirements
(aged ≥18 years), scalability (access to email/Internet)
and data integrity (completion of questionnaires at base-
line). Recruitment was initially planned only from do-
nors registered at a static donor centre. However, only
about half of the donors from this source attended one
of these centres during the recruitment period, rather
than the approximately 70 % that would have been needed
to meet recruitment targets. Given the shortfall in recruit-
ment from the static donor centres, extra recruitment
strategies were employed which focused on targeting
groups of mobile session donors who were most likely to
be able to transfer to a static donor centre to take part in
the study and/or were of a significant size. The take-up
rate in these groups of donors, while lower than that for
the static centre donors, contributed almost 20 % of the
total participants recruited into INTERVAL.
The trial’s participation rates varied according to
the groups of donors targeted. Furthermore, donors
recruited from different sources showed distinct char-
acteristics; this was especially the case for the Mobile
(platelet) and ‘No invitation’ participants. For the former
group, this can probably be attributed to the commitment
that is required to give platelet donations up to every
2 weeks and NHSBT’s platelet donor recruitment strategy.
We compared the characteristics of participants ran-
domised into INTERVAL with the general donor popu-
lation, focusing on features potentially relevant to trial
outcomes. Although we found that the populations
were generally similar, there were subtle differences in
sex and age distributions. Moreover, a comparison of
donation history indicated that the INTERVAL partici-
pants represented a longer-standing group of donors
who had donated more frequently. It is possible that a
more dedicated group of donors may make greater ef-
forts (or have fewer other commitments) to attend
more frequent donations. Hence, any impact observed
in INTERVAL of inviting donors to give blood more
frequently to increase blood supplies may be greater
than that achieved in the general donor population.
The data in this paper, however, suggest that the
INTERVAL cohort were similarly resilient to iron defi-
ciency following repeat donations as the general donor
population, with deferral rates for low haemoglobin
levels similar in both groups.
Donor centres offer permanent sites for blood dona-
tion, which are typically open daily during the working
week in specific geographical locations across England.
This is in contrast to temporary ‘mobile’ donation ses-
sions in community venues, which visit locations at
weekly or less frequent intervals. It is possible that the
trial’s requirement to attend a static donor centre con-
tributed, in part, to the subtle differences in characteris-
tics of INTERVAL participants compared to the general
donor population. In recent years, NHSBT’s strategy has
been to increase the proportion of whole-blood dona-
tions collected in static donor centres; in 2015/2016 ap-
proximately 15 % of whole-blood donations were made
at donor centres, and the target is to increase this to
25 % in 2020/2021. It is possible, therefore, that the
INTERVAL cohort may be more representative of the
general donor population in the future.
Not all donors who consented to participate in INTER-
VAL were randomised. Compared to the randomised
group, consenting but non-randomised participants had a
higher proportion of younger donors, a shorter history of
donation, a smaller proportion of more frequent donors, a
lower average number of donations and a higher propor-
tion of non-white ethnic groups. Perhaps surprisingly, a
greater proportion of randomised participants had a
Table 5 Demographic characteristics of the INTERVAL cohort by recruitment sourcea (Continued)
Demographics INTERVAL cohort
n (%) or mean (SD) Centre Mobile (platelet) Mobile (10-mile) Mobile (30-mile) No invitation
Donations (during the 2 years prior to baseline)
All donations 3.47 (1.87) 4.28 (1.68) 3.06 (1.66) 3.35 (1.75) 2.39 (2.54)
Whole-blood donations 3.38 (1.73) 4.13 (1.51) 3.05 (1.65) 3.33 (1.73) 2.15 (1.92)
Other donations 0.08 (0.89) 0.15 (1.08) 0.01 (0.29) 0.02 (0.32) 0.23 (1.87)
Deferrals (during the 2 years prior to baseline)
Deferral for low haemoglobin 2597 (8.1 %) 73 (4.2 %) 242 (4.6 %) 119 (4.9 %) 277 (3.8 %)
Any other deferral 10,174 (31.9 %) 461 (26.5 %) 1238 (23.6 %) 660 (27.4 %) 2095 (28.4 %)
Length of NHSBT donation history at baseline (years) 11.2 (8.4) 14.2 (8.4) 10.2 (8.1) 11.4 (9.1) 7.78 (7.71)
aFor definitions see footnotes to Table 3
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correspondence address that was 10 miles or more from a
static donor centre.
Conclusions
It is important that the conclusions from the analysis of
RCT data can be appropriately generalised and, for this
reason, RCTs should try to establish formally how repre-
sentative the individuals recruited are of the target popu-
lation. This is often not easy to achieve, but we had the
opportunity to do this because of the existence of a na-
tional database. There was broad similarity of partici-
pants in INTERVAL with the general blood donor
population of England, notwithstanding some differences
in age, sex and donation history. Factors which differ be-
tween the recruited sample and the target population
will need to be investigated as potential effect modifiers
in the analysis of the trial data (using subgroup analyses
or tests of interaction). However, it is not possible to
rule out differences in unmeasured variables or unob-
servable characteristics, so there always remains an
element of uncertainty in generalising the results of
RCTs. Furthermore, we acknowledge that the extrapo-
lation of INTERVAL’s results to blood services outside
England and Wales is not straightforward, because
blood services differ in several important respects, such
as donor selection practices and policies about allow-
able inter-donation intervals.
Additional file
Additional file 1: INTERVAL trial – statistical analysis plan for principal
paper. (PDF 74 kb)
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